Efficacy of atovaquone against Babesia gibsoni in vivo and in vitro

• Published in: Veterinary parasitology 2004-09, Vol.124 (1), p.9-18
• Main Authors: Matsuu, Aya, Koshida, Yushi, Kawahara, Megumi, Inoue, Kenichi, Ikadai, Hiromi, Hikasa, Yoshiaki, Okano, Shozo, Higuchi, Seiichi
• Format: Article
• Language: English
• Subjects: 1, 4-hydroxynaphthoquinone; Administration, Oral; Animals; antiprotozoal agents; Antiprotozoal Agents - pharmacology; Antiprotozoal Agents - therapeutic use; Atovaquone; Babesia - drug effects; Babesia gibsoni; babesiosis; Babesiosis - drug therapy; Babesiosis - veterinary; Canine babesiosis; Chemotherapy; Dog Diseases - drug therapy; Dogs; dose response; Dose-Response Relationship, Drug; drug efficacy; drug evaluation; Drug Resistance; drug therapy; Female; in vitro studies; in vivo studies; naphthoquinones; Naphthoquinones - pharmacology; Naphthoquinones - therapeutic use; parasitemia; Parasitic Sensitivity Tests - veterinary; Thrombocytopenia; Thrombocytopenia - parasitology; Thrombocytopenia - veterinary; Treatment Outcome
• ISSN: 0304-4017; 1873-2550
• DOI: 10.1016/j.vetpar.2004.07.005

The therapeutic efficacy of atovaquone against Babesia gibsoni was examined in three dogs experimentally infected with B. gibsoni isolated from naturally infected dogs in Aomori Prefecture, Japan. Once parasitemia reached 10%, atovaquone was administered orally (30 mg/kg twice daily for 7 days). Within 2 days of atovaquone treatment, the parasite disappeared from blood smears without any clinical side effects. Anemia and thrombocytopenia were significantly improved in all the dogs. However, a polymerase chain reaction assay revealed that a B. gibsoni marker gene was intermittently present in peripheral blood after atovaquone therapy, indicating that the organism had not been eliminated, and parasites reappeared in blood smears 33 days after the last treatment. To investigate the change in sensitivity against atovaquone, an in vitro sensitivity test was performed using peripheral blood obtained from an untreated dog that was infected with the original parasite isolate, and from two of the experimentally infected and atovaquone-treated animals (blood was collected at the time of the post-treatment recurrence of the B. gibsoni infection). Atovaquone was added to the culture medium to final concentrations of 0.1, 1, 10, 100, and 1000 nM. For the untreated parasites, complete growth inhibition occurred at 1000 nM of atovaquone, whereas the recurrent parasites were inhibited by only 39.52 ± 8.34% and 31.31 ± 8.14% at this concentration after 48 h of incubation. Thus, the recurring parasites were less sensitive to atovaquone than the untreated originally isolated parasites.